Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Current Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Total Current Liabilities for 15 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 45.97% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 45.97% decrease, with the full-year FY2025 number at $2.3 million, down 3.55% from a year prior.
  • Total Current Liabilities was $1.5 million for Q3 2025 at IGC Pharma, down from $1.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $2.8 million in Q3 2024 to a low of $1.3 million in Q4 2021.
  • A 5-year average of $2.0 million and a median of $2.1 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 52.39% in 2023, then plummeted 45.97% in 2025.
  • IGC Pharma's Total Current Liabilities stood at $1.3 million in 2021, then increased by 6.02% to $1.4 million in 2022, then soared by 42.77% to $1.9 million in 2023, then surged by 37.24% to $2.7 million in 2024, then plummeted by 43.02% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Current Liabilities are $1.5 million (Q3 2025), $1.7 million (Q2 2025), and $2.3 million (Q1 2025).